Brind.

Annovis Bio Presents Alzheimer's Drug Research at CTAD Conference

1 report, 1 independent Updated Oct 22

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Annovis Bio, Inc. announced it will attend the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, MA. Alexander Morin and Cheng Fang will present research findings regarding buntanetap, an oral therapy being investigated for neurodegenerative diseases like Alzheimer’s and Parkinson’s diseases.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The presentations detail the clinical trial design and baseline characteristics of buntanetap’s pivotal study in treating early Alzheimer’s patients. This research contributes to the ongoing advancement of small-molecule drug candidates for neurodegenerative conditions.

From manilatimes.net

Who's involved

Cheng FangChief Scientific Officer presenting research on buntanetap
Alexander MorinDirector of Strategic Communications presenting research on buntanetap

Keep exploring

The entities involved

Boston
capital and largest city of Massachusetts, United States
- Artist from Boston performed in Dayton on October 31, 2026.02:41
- Students from Northeastern University attended a demonstration in Boston on October 31, 2026.00:50
Cheng Fang
researcher (ORCID 0000-0002-9767-2043)

Nothing else this week.
Alexander Morin
researcher

Nothing else this week.

Coverage

Newest first; wire copies grouped

Oct 22manilatimes.net